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ABSTRACT Pulmonary embolism (PE) is a serious and costly disease for patients and healthcare
systems. Guidelines emphasise the importance of differentiating between patients who are at high risk of
mortality (those with shock and/or hypotension), who may be candidates for thrombolytic therapy or
surgery, and those with less severe presentations. Recent clinical studies and guidelines have focused
particularly on risk stratification of intermediate-risk patients. Although the use of thrombolysis has been
investigated in these patients, anticoagulation remains the standard treatment approach. Individual risk
stratification directs initial treatment. Rates of recurrence differ between subgroups of patients with PE;
therefore, a review of provoking factors, along with the risks of morbidity and bleeding, guides the
duration of ongoing anticoagulation. The direct oral anticoagulants have shown similar efficacy and, in
some cases, reduced major bleeding compared with standard approaches for acute treatment. They also
offer the potential to reduce the burden on patients and outpatient services in the post-hospital phase.
Rivaroxaban, dabigatran and apixaban have been shown to reduce the risk of recurrent venous
thromboembolism versus placebo, when given for >12 months. Patients receiving direct oral anticoagulants
do not require regular coagulation monitoring, but follow-up, ideally in a specialist PE clinic in
consultation with primary care providers, is recommended.
@ERSpublications
Direct oral anticoagulants have the potential to improve management of patients with
pulmonary embolism http://ow.ly/NV7K6
Introduction
Pulmonary embolism (PE) is a well-recognised and significant cause of morbidity and mortality, estimated
to be associated with more than 300000 deaths per year in Europe alone [1]. Many fatal cases are not
diagnosed pre mortem because of the nonspecific clinical symptoms with which patients often present [2].
In nonfatal cases, PE is associated with a risk of recurrent venous thromboembolism (VTE) (i.e. deep vein
thrombosis (DVT) or PE) [3] and the development of complications such as chronic thromboembolic
pulmonary hypertension (CTEPH), which, although uncommon, is associated with a relatively high
morbidity and mortality rate [4]. DVT, which often accompanies PE [5], leads to post-thrombotic
syndrome in up to 50% of patients within 1 year, substantially compromising quality of life [6]. PE also
carries a substantial economic burden. A recent analysis in Germany calculated the cost of the first year of
PE treatment to be in excess of €20000 [7].
Several clinical bodies have developed guidelines for the management of PE [8, 9], and an update to the
2008 European Society of Cardiology (ESC) guidelines has recently been published [2, 10]. Much of the
guidance in the public domain predates the availability of direct oral anticoagulants (OACs) that now
provide an alternative to the standard therapy of low molecular weight heparins (LMWHs) and vitamin K
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antagonists (VKAs). New data on the direct OACs rivaroxaban, apixaban, edoxaban and dabigatran are
rapidly emerging, with rivaroxaban, dabigatran and apixaban now approved in Europe and the USA for
the treatment and secondary prevention of recurrent DVT and PE in adults.
This review summarises the challenges and recent developments in the management and treatment of PE,
with an emphasis on individual risk stratification and recurrence risk, and discusses the potential
implications of the direct OACs for clinical practice.
Diagnosis and risk stratification of PE
Clinical signs and symptoms and prognostic risk stratification
The ESC guidelines for the diagnosis of clinically suspected PE are shown in figure 1. The clinical signs
and symptoms of PE may be nonspecific [11], and diagnostic confirmation using imaging and laboratory
tests is required [2, 12]. Dyspnoea, tachypnoea, chest pain, cough, haemoptysis, tachycardia, syncope and
respiratory crepitations are all common symptoms of PE, but none is unique to the condition [2, 11, 13].
Even large emboli may be asymptomatic, but syncope or near-syncope, hypotension, extreme hypoxaemia,
electromechanical dissociation or cardiac arrest is suggestive of a massive or “high-risk” PE [11].
The 2008 ESC guidelines suggested that PE severity should be expressed as an individual estimate of
PE-related early mortality risk rather than anatomical burden and distribution. PE can be stratified by risk
of early death (defined as in-hospital or 30-day mortality) based on the presence of risk markers. These
include shock or hypotension, signs of right ventricular dysfunction and biochemical markers of
myocardial injury. Haemodynamically unstable patients have a >15% risk of death in the first 30 days after
hospitalisation [2]. Those without shock or hypotension but with signs of right ventricular dysfunction or
myocardial injury are at intermediate risk and have a 3–15% risk of 30-day mortality. The absence of all
these clinical parameters is consistent with a low-risk PE and confers a 30-day mortality risk of <1% [2].
According to the updated 2014 ESC guidelines, the simplified pulmonary embolism severity index (PESI)
is also recommended as a means of distinguishing between patients at a high risk of death from PE and
those at a lower risk [10, 14].
In the 2014 recommendations, the risk-stratification algorithm has been refined for those at intermediate
risk [10]. In particular, further risk stratification into “intermediate-low” and “intermediate-high”
categories can be considered to further aid management strategy decisions. Patients are subclassified as
intermediate-high risk if they have a clinical risk score suggestive of PE and are positive for signs of right
ventricular dysfunction, both by imaging and by means of cardiac laboratory biomarkers indicative of
myocardial injury or heart failure as a result of right ventricular dysfunction. Intermediate-low risk
patients have a clinical risk score suggestive of PE but may have either one or none of these indicators for
right ventricular dysfunction [10].
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FIGURE 1 European Society of Cardiology guidelines for the diagnosis of a) clinically suspected high-risk pulmonary embolism (PE) and b) clinically suspected
non-high-risk PE. #: i.e. with shock and/or hypotension. ¶: not available if the patient’s condition allows bedside diagnostic tests only. +: transoesophageal
echocardiography may detect pulmonary arterial thrombi in a significant proportion of patients with right ventricular (RV) overload and PE that is ultimately
confirmed by spiral computed tomography (CT). Confirmation of deep vein thrombosis with bedside compression ultrasound could also assist
decision-making. §: two alternative classification schemes may be used for clinical probability assessment; i.e. a three-level scheme (low, intermediate or high) or
a two-level scheme (PE unlikely or PE likely). ƒ: e.g. Wells score. Adapted from [2] and [10].
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To assist with identifying this substantial group of patients, BOVA et al. [15] developed a prognostic model
for intermediate-risk PE based on the clinical presentation and assessment of right ventricular dysfunction
and myocardial injury. The primary outcome (the composite of PE-related death, haemodynamic collapse
or recurrent PE within 30 days of follow-up) occurred in 6.9% of patients, and predictors of complications
included a systolic blood pressure of 90–100 mmHg, elevated cardiac troponin and right ventricular
dysfunction. The model identified three stages (I, II and III) associated with 30-day PE-related
complication rates of 4.2%, 10.8% and 29.2%, respectively, thereby offering clinicians a simple grading
system to identify patients with intermediate-risk PE [15]. According to a recent meta-analysis, computed
tomography (CT)-detected right ventricle dilation was associated with an increased 30-day all-cause
mortality risk in patients with PE (OR 2.08, 95% CI 1.63–2.66; p<0.00001), including in
haemodynamically stable patients (OR 1.64, 95% CI 1.06–2.52; p=0.03), as well as an increased 30-day risk
of death due to PE (OR 7.35, 95% CI 3.59–15.09; p<0.00001). An association between right ventricle
dilation and 3-month mortality rates was also observed (OR 4.65, 95% CI 1.79–12.07; p=0.002), thus
indicating that right-to-left ventricle dilation as assessed by CT angiography can be used to assess the risk
of death in haemodynamically stable patients with PE [16].
Confirmation of suspected high-risk (haemodynamically unstable) PE
In haemodynamically unstable patients with a high risk of PE, diagnostic confirmation is still required
[17]. Diagnosis should ideally be confirmed by CT pulmonary angiography (CTPA) [2]. Echocardiography
is suggested as the preferred alternative if CTPA cannot be performed (fig. 1a) [2]. This is to confirm right
ventricular overload. Evidence of acute pulmonary hypertension and right ventricular overload on the
electrocardiogram of an unstable patient may be sufficient to presume high-risk PE, but only when other
confirmatory tests are unavailable [2]. Levels of cardiac markers of right ventricular dysfunction (e.g.
increased levels of brain natriuretic peptide) and myocardial injury (presence of troponin T or I) also
gauge the severity of PE [2]. In a prospective, multicentre cohort study that included 688 patients,
N-terminal pro-brain natriuretic peptide plasma concentrations of 600 pg·mL−1 were identified as the
optimal cut-off value for the identification of elevated risk [18].
Confirmation of suspected non-high-risk (haemodynamically stable) PE
In haemodynamically stable patients, scoring systems, such as the two-level Wells score for PE (table 1)
[19] and the simplified Geneva score [20], are useful for estimating the clinical probability of PE. The
recommended approach for confirming or refuting non-high-risk PE is to combine a clinical probability
score with D-dimer testing and CTPA where indicated (fig. 1b) [2]. In a large, prospective cohort study,
this combination guided clinical management decisions effectively in 98% of cases [21]. A high-sensitivity
D-dimer assay can exclude PE without further testing in ∼30% of cases with a low or intermediate clinical
probability score [2, 22]. In a community study, a Wells score ⩽4 combined with a negative D-dimer test
safely ruled out PE in 94.5% of patients with suspected PE [23]. The combination of negative
high-sensitivity D-dimer and negative CTPA equates to a <1% likelihood of VTE [17]. In those with a
high clinical probability score or an elevated D-dimer concentration despite a low or intermediate clinical
probability, further investigations are required [2]. CTPA is usually recommended but is contraindicated in
patients with severe renal impairment (creatinine clearance (CrCl) 15–29 mL·min−1) or allergy to contrast
media, in those unable to lie flat, and is debatable in pregnancy. In these patients, ventilation–perfusion
scanning may be considered [9]. Doppler ultrasound scanning of the legs should be considered as an
adjunct where CTPA is contraindicated, as up to 70% of patients with symptomatic PE have a
demonstrable DVT [24].
TABLE 1 Two-level Wells score for estimating the clinical probability of pulmonary embolism (PE)
Parameter Score
Clinically suspected DVT 3
Alternative diagnosis less likely than PE 3
Rapid heart rate 1.5
Immobilisation for >3 days or surgery within the past 4 weeks 1.5
History of VTE 1.5
Haemoptysis 1
Malignancy 1
After adding the total points together, a score >6 indicates a high probability of PE; 2−6 a moderate
probability; and <2 a low probability. The NICE 2012 guidelines suggest that a score of >4 points indicates PE
likely and ⩽4 points indicates PE unlikely [9, 19]. DVT: deep vein thrombosis; VTE: venous thromboembolism.
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Initial treatment of PE
Patients with high-risk PE accompanied by shock and/or hypotension are candidates to receive immediate
intravenous unfractionated heparin (UFH) and thrombolytic therapy or surgical embolectomy [2, 12]. By
contrast, patients with intermediate- or low-risk PE (i.e. without shock or hypotension) generally receive
anticoagulant treatment, which should be initiated when PE is strongly suspected, even if the diagnostic
work-up is ongoing [2, 12], unless imaging can be accessed immediately [9].
There has been recent interest in thrombolytic therapy for the intermediate-risk group. In the MOPETT
(Moderate Pulmonary Embolism Treated with Thrombolysis) trial, adding “low-dose” recombinant tissue
plasminogen activator to anticoagulation led to earlier hospital discharge (after 2.2 days versus 4.9 days;
p<0.001) and significantly lower composite rates of pulmonary hypertension and recurrent PE (16% versus
57%; p<0.001) and composite rates of death and recurrent PE (1.6% versus 10%; p=0.0489) at 28 months
compared with anticoagulation alone, with no bleeding in either group [25]. Two small randomised
studies of thrombolysis in intermediate-risk patients with PE, ULTIMA (Ultrasound Accelerated
Thrombolysis of Pulmonary Embolism) (recombinant tissue plasminogen activator plus UFH compared
with UFH alone) and TOPCOAT (Tenecteplase or Placebo: Cardiopulmonary Outcomes at Three Months)
(tenecteplase plus LMWH compared with LMWH alone), also reported positive outcomes with
thrombolytic regimens [26, 27]. In the larger randomised PEITHO (Pulmonary Embolism Thrombolysis)
study, all patients were classified as intermediate-high risk according to the ESC guidelines. Patients
received heparin with or without standard weight-based i.v. tenecteplase, and had a lower combined risk
of mortality and haemodynamic collapse (2.6% versus 5.6%; p=0.02) with thrombolysis, but also a
significant increase in non-intracranial major bleeding (6.3% versus 1.2%; p<0.001) and stroke (2.4% versus
0.2%; p=0.003) [28]. By day 30, 2.4% and 3.2% of patients in the thrombolysis and control groups,
respectively, had died (p=0.42).
Based on these observations, the 2014 ESC guidelines do not routinely recommend thrombolysis as
primary treatment in patients with intermediate-high-risk PE; however, thrombolysis can be considered if
clinical signs of haemodynamic decompensation appear [10].
The conventional treatment protocol for non-high-risk patients with PE involves initial anticoagulation
with a parenteral agent, most commonly a LMWH or fondaparinux, for at least 5 days, with a VKA, often
warfarin, given concurrently and starting as soon as possible. LMWH is discontinued when the
international normalised ratio is stable between 2.0 and 3.0 for at least 24 h, and the VKA dose is adjusted
to remain within this range [2, 12]. This approach balances the need for rapid initial anticoagulation and
clot stabilisation, provided by LMWH, with the relative convenience of an oral agent for ongoing therapy.
However, it is also relatively cumbersome and time-consuming for both patients and physicians.
Rivaroxaban, apixaban and dabigatran are approved for the treatment of PE (and DVT) and the
prevention of recurrent DVT and PE in adults in Europe and the USA. The potential advantages of
rivaroxaban, apixaban, edoxaban (direct factor Xa inhibitors) and dabigatran (direct thrombin inhibitor)
include a similarly rapid onset of action to LMWH but with oral administration [29]. Unlike the VKAs,
direct OACs offer predictable pharmacokinetic and pharmacodynamic properties and a lack of extensive
drug and food interactions; therefore, removing the requirement for routine coagulation monitoring and
dose adjustment (although dose reductions are specified in some cases, e.g. renal impairment) (table 2
and 3) [29–39]. However, concerns have been raised about the lack of a specific agent to reverse the effects
of the direct OACs in the event of a bleeding emergency [40].
Both rivaroxaban and apixaban have been evaluated as single-drug approaches (in contrast to standard
therapy) in randomised, phase III clinical trials. The EINSTEIN PE study evaluated rivaroxaban
specifically for the treatment of PE [31], whereas AMPLIFY (Apixaban for the Initial Management of
Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) assessed outcomes with
apixaban in patients with DVT and/or PE [32]. EINSTEIN PE was an open-label study that included
patients with confirmed acute symptomatic PE with or without symptomatic DVT, but excluded patients
scheduled to receive thrombolysis or surgery [31]. Patients received either enoxaparin 1 mg·kg−1 twice
daily, overlapping with and eventually succeeded by dose-adjusted VKA (warfarin or acenocoumarol), or
single-drug rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily. The rivaroxaban
doses were chosen based on the results of dose-ranging studies [41, 42] and pharmacokinetic modelling
[43], to balance the strong antithrombotic effect needed in the acute phase of treatment with the
requirement to manage the risk of bleeding during longer-term therapy. Treatment continued for 3, 6 or
12 months according to each patient’s clinical risk for recurrent VTE and bleeding [31]. Bleeding was
defined as major if it was associated with a ⩾2 g·dL−1 fall in haemoglobin, led to transfusion of ⩾2 units
of packed red cells or whole blood, involved a critical organ or led to death. Clinically relevant bleeding
encompassed major bleeding and any non-major bleeding that was considered clinically relevant (e.g.
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requiring an unscheduled medical contact or procedure, temporary cessation of study drug, or associated
with pain or impairment of daily activities).
At baseline, ∼25% of patients in EINSTEIN PE had an embolus involving multiple lobes and more than
one-quarter of the pulmonary vasculature, and a similar proportion had confirmed DVT in addition to the
PE. Rivaroxaban was noninferior to enoxaparin/VKA for the incidence of recurrent symptomatic VTE
(2.1% versus 1.8%, hazard ratio (HR) 1.12, 95% CI 0.75–1.68; p=0.003 for noninferiority) [31]. Efficacy was
consistent regardless of PE severity. There was a similar incidence of clinically relevant bleeding in both
treatment arms (10.3% versus 11.4%, HR 0.90, 95% CI 0.76–1.07; p=0.23), but a 51% relative risk reduction
(RRR) in major bleeding in the rivaroxaban arm compared with standard therapy (1.1% versus 2.2%, HR
TABLE 2 Clinically important properties of oral anticoagulants (OACs) with reference to phase III venous thromboembolism
(VTE) treatment studies [30–34] and published pharmacology data [29, 35–39]
Rivaroxaban
(Xarelto; Bayer
HealthCare/Janssen
Pharmaceuticals)
Apixaban
(Eliquis;
Bristol-Myers
Squibb/Pfizer)
Edoxaban
(Lixiana; Daiichi
Sankyo)
Dabigatran
etexilate
(Pradaxa;
Boehringer
Ingelheim)
Warfarin
(generic)
Mechanism of
action
Direct factor Xa
inhibitor
Direct factor Xa
inhibitor
Direct factor Xa
inhibitor
Direct thrombin
inhibitor
Vitamin K antagonist
Currently
approved for VTE
treatment in Europe
and the USA?
Yes Yes No Yes Yes
Time to maximum
concentration h
2–4 3–4 1–2 0.5–2 Several days
Half-life h 5–13 ∼12 8–10 12–14 ∼40
Proportion of
unchanged drug
excreted renally %
33# 27 35 85 Minor only
VTE treatment
approach and dose
Single drug; 15 mg
twice daily for
3 weeks, then 20 mg
once daily
Single drug;
10 mg twice daily
for 7 days, then
5 mg twice daily
Dual drug; after median
7 days of parenteral
anticoagulation, 60 mg
once daily
Dual drug; after
5–10 days of
parenteral
anticoagulation,
150 mg twice daily
Dual drug; start
alongside parenteral
anticoagulant,
discontinue latter after
⩾5 days when INR ⩾2
for ⩾2 days, adjust
dose to maintain INR
2–3
Dose adjustments for
VTE treatment
None No reduced dose
tested in phase III
trials
30 mg once daily tested
in patients with CrCl
30–50 mL·min−1 or body
weight ⩽60 kg or
receiving concomitant
strong P-gp inhibitors
No reduced dose
tested in phase III
trials
Frequent, guided by
the INR
Incidence of clinically
relevant/major
bleeding in VTE
treatment studies %
10.3/1.1
(EINSTEIN PE) and
8.1/0.7
(EINSTEIN DVT) as a
single drug
4.3/0.6 (AMPLIFY)
as a single drug
8.5/1.4 (Hokusai-VTE)
after parenteral
induction
5.6/1.6 (RE-COVER)
after parenteral
induction
Up to 11.4/2.2 in
studies of direct OACs
after parenteral
induction
Reversal in bleeding
emergency
PCC, aPCC or rFVIIa suggested for rivaroxaban, apixaban and dabigatran
(specific antidotes in development)
PCC (vitamin K is slow)
Food effect No interactions; take
rivaroxaban 15 mg
and 20 mg doses
with food
No interaction; apixaban, edoxaban and dabigatran can
be taken with or without food
Affected by many
common foods, e.g.
cranberry juice and
vegetables containing
high levels of vitamin K
Relevant drug
interactions
Factor Xa inhibitors: strong inhibitors of CYP3A4 and P-gp: azole
antimycotics (e.g. ketoconazole) and HIV protease inhibitors
(e.g. ritonavir)
Dabigatran: strong
P-gp inhibitors and
inducers
Multiple
Contraindicated/not recommended conditions are listed in table 3. INR: international normalised ratio; CrCl: creatinine clearance; P-gp:
P-glycoprotein; PCC: prothrombin complex concentrate; aPCC: activated prothrombin complex concentrate; rFVIIa: recombinant activated
factor VII; CYP3A4: cytochrome P450 3A4. #: 33% is also excreted renally as inactive metabolites.
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0.49, 95% CI 0.31–0.79; p=0.003) [31]. In the EINSTEIN DVT trial, which included patients with DVT but
not PE, the incidence of the principal safety outcome (major or non-major clinically relevant bleeding) was
similar in patients receiving rivaroxaban compared with those receiving standard therapy [30].
AMPLIFY was a double-blind study, in which patients with confirmed DVT and/or PE received apixaban
or standard therapy for 6 months [32]. Approximately one-third of patients had PE, of whom ∼26% also
had DVT and ∼37% had extensive lung involvement. As with rivaroxaban, single-drug apixaban was given
at an intensive initial dose of 10 mg twice daily for 7 days, and then continued at 5 mg twice daily. In the
overall population, apixaban was noninferior to standard therapy for the incidence of recurrent VTE or
VTE-related death (2.3% versus 2.7%, relative risk 0.84, 95% CI 0.60–1.18; p<0.001 for noninferiority) and
was associated with a significant reduction in the incidence of major bleeding (0.6% versus 1.8%, relative
risk 0.31, 95% CI 0.17–0.55; p<0.001) and clinically relevant bleeding (4.3% versus 9.7%, relative risk 0.44,
95% CI 0.36–0.55; p<0.001) [32].
In contrast to rivaroxaban and apixaban, dabigatran and edoxaban were studied in randomised, phase III
trials as part of a dual-drug regimen. In the double-blind RE-COVER (Efficacy and Safety of Dabigatran
Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism) study,
heparin induction was given for 5–11 days before transition to 6 months of dabigatran 150 mg twice daily
or warfarin [33]. ∼31% of patients had PE with or without DVT. Both study arms were similarly efficacious
TABLE 3 Contraindicated/not recommended conditions for use of oral anticoagulants with reference to published
pharmacology data [29, 35–39]
Rivaroxaban (Xarelto;
Bayer HealthCare/
Janssen
Pharmaceuticals)
Apixaban (Eliquis;
Bristol-Myers Squibb/
Pfizer)
Edoxaban (Lixiana;
Daiichi Sankyo)
Dabigatran etexilate
(Pradaxa; Boehringer
Ingelheim)
Warfarin (generic)
Age <18 years
CrCl <15 mL·min−1
Age <18 years
CrCl <15 mL·min−1
To be confirmed (not yet
licensed for any indication
in Europe)
Age <18 years
CrCl <30 mL·min−1
Hypersensitivity to
warfarin or excipients
Haemorrhagic stroke
Hypersensitivity to the
active substance or
excipients
Clinically significant active
bleeding or lesions at risk
of clinically significant
bleeding
Concomitant strong
inhibitors of both CYP3A4
and P-gp
Concomitant dronedarone
Hepatic disease
associated with
coagulopathy and
clinically relevant
bleeding risk, including
cirrhotic patients with
Child–Pugh B or C
Malignant neoplasms at
high risk of bleeding
Pregnancy or
breast feeding
Hepatic disease
associated with
coagulopathy and
clinically relevant
bleeding risk
Severe hepatic
impairment or dialysis
Elevated liver enzymes
(ALT/AST >2×ULN) or
total bilirubin ⩾1.5×ULN
Hypersensitivity to active
substance or excipients
Clinically significant active
bleeding
Concomitant strong
inhibitors of both CYP3A4
and P-gp
Increased bleeding risk
for other reasons
Pregnancy or
breast feeding
Hypersensitivity to the
active substance or any of
the excipients
Clinically significant active
bleeding or a lesion or
condition at significant
risk of major bleeding
Hepatic impairment or
liver disease expected to
impact survival
Concomitant treatment
with other anticoagulants
(except when switching)
or systemic ketoconazole,
cyclosporine,
itraconazole, tacrolimus
or dronedarone
Pregnancy or
breast feeding
Clinically significant
bleeding
Use within 72 h of surgery
with risk of severe
bleeding
Use within 48 h
post-partum
Pregnancy or
breast feeding
Drugs where interactions
lead to a significantly
increased risk of bleeding
(multiple)
CrCl: creatinine clearance; CYP3A4: cytochrome P450 3A4; P-gp: P-glycoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase;
ULN: upper limit of normal.
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for the incidence of recurrent VTE or VTE-related death (2.4% versus 2.1%, HR 1.10, 95% CI 0.65–1.84;
p<0.001 for noninferiority) [33]. Major bleeding occurred with a similar incidence between the treatment
arms (1.6% versus 1.9%, HR 0.82, 95% CI 0.45–1.48), whereas clinically relevant bleeding was significantly
reduced in the dabigatran arm (5.6% versus 8.8%, HR 0.63, 95% CI 0.47–0.84) [33]. The outcomes of a
second trial, RE-COVER II, and a pooled analysis of both studies, supported these results [44].
The double-blind Hokusai-VTE study compared edoxaban, after ⩾5 days of heparin induction, with
standard heparin/warfarin given for 3–12 months as judged clinically appropriate [34]. ∼40% of patients
had PE, and of these ∼46% had anatomically extensive disease. The edoxaban dose was 60 mg once daily,
but in patients with CrCl 30–50 mL·min−1 or body weight ⩽60 kg or those receiving potent P-glycoprotein
inhibitors (e.g. systemic ketoconazole, cyclosporin or dronedarone) the dose was reduced to 30 mg once
daily. Heparin/edoxaban was found to be noninferior to heparin/warfarin for the incidence of recurrent
VTE or VTE-related death following 12 months’ treatment (3.2% versus 3.5%, HR 0.89, 95% CI 0.70–1.13;
p<0.001 for noninferiority) [34]. Efficacy was similar in patients with PE and in those who received the
lower edoxaban dose. The incidence of clinically relevant bleeding events was significantly lower in the
edoxaban group (8.5% versus 10.3%, HR 0.81, 95% CI 0.71–0.94; p=0.004), but the incidence of major
bleeding was similar to standard therapy (1.4% versus 1.6%, HR 0.84, 95% CI 0.59–1.21; p=0.35) [34].
Long-term prevention of recurrent VTE after an initial PE
Patients who have had an initial PE remain at risk of recurrence without continued therapy [3, 45]. ∼30%
of PEs are unprovoked [2], with an associated two- to three-fold increased risk of recurrence compared
with patients with an initial thromboembolism associated with risk factors [46]. Recurrence is more
common in patients with persistent risk factors (e.g. cancer or elevated antiphospholipid antibodies) than
in those with transient risk factors (e.g. surgery) [12, 47]. Older age, which is strongly associated with a
first VTE, appears to be less influential on the risk of recurrence [48]. By contrast, although sex is not a
major risk factor for initial VTE [48], men have a markedly higher risk of recurrence than women after an
initial unprovoked VTE [49].
The optimal duration of anticoagulation remains uncertain. Guidelines generally suggest a minimum of
3 months, a length of treatment that is associated with a lower risk of VTE recurrence than shorter
durations [46], or long term if the initial event was idiopathic or if risk factors persist (table 4) [2, 12, 46,
50–53]. Patients with CTEPH should remain on lifelong anticoagulation [54]. As yet, there are no clinical
data on the effect of direct OACs on VTE-related sequelae.
Judging the benefit of continued anticoagulation in elderly patients, those with severe renal impairment,
patients with cancer or those who are immobilised is particularly challenging because these factors
increase the risks of both recurrent VTE and serious anticoagulant-related bleeding [12, 51, 52]. Of note, a
population-based case–control study showed that patients with cancer receiving chemotherapy have an
approximately six-fold increase in the adjusted (for location at VTE onset) risk ratio for VTE compared
with healthy controls [55]. In patients with cancer who develop VTE, guidelines recommend LMWH over
warfarin and direct OACs owing to limited data [2, 12]. The CLOT AF trial suggested that in patients with
cancer and acute VTE, dalteparin was more effective than coumarin at reducing the risk of recurrent
TABLE 4 Risk factors associated with recurrent venous thromboembolism (VTE) and
anticoagulant-related bleeding [2, 12, 46, 50–53]
Recurrent VTE Serious or fatal bleeding Both recurrent VTE and
serious bleeding
Initial unprovoked VTE Low platelet count Increased age
Initial proximal DVT or PE Previous bleeding Cancer
Thrombophilia Recent major bleeding Immobilisation
Residual proximal thrombosis Previous stroke Recent surgery (transient)
Male sex Hepatic failure Severe renal impairment
Elevated D-dimer concentrations
when not receiving anticoagulation
Pregnancy
Anticoagulation lasting<3 months
Diabetes
Abnormal prothrombin time
Thrombocytopenia
Poor anticoagulant control
Comorbidity
Anaemia
DVT: deep vein thrombosis; PE: pulmonary embolism.
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thromboembolism without increasing the risk of bleeding [56]; however, no studies directly comparing
LMWH to direct OACs are available. The 2014 ESC guidelines state that the decision for chronic
anticoagulation (i.e. continuation of LMWH, transition to VKA or discontinuation of anticoagulation)
should be made on a case-by-case basis after considering the success of anticancer therapy, the estimated
risk of recurrence of VTE, the bleeding risk and the preference of the patient [10]. The largest dataset of
patients with cancer from studies of direct OACs for VTE treatment comes from a pooled analysis of the
EINSTEIN DVT and EINSTEIN PE rivaroxaban studies. A total of 655 patients with active cancer (at
baseline or diagnosed during the study) and 469 patients with a history of cancer were randomised. In
patients with active cancer (diagnosed at baseline or during treatment), the incidences of recurrent VTE
and clinically relevant bleeding were numerically lower in patients allocated to rivaroxaban compared with
patients assigned to enoxaparin/VKA (5% versus 7%, HR 0.67, 95% CI 0.35–1.30, and 14% versus 16%,
HR 0.80, 95% CI 0.54–1.20, respectively). Patients with active cancer receiving rivaroxaban had a
significantly lower incidence of major bleeding than those receiving standard therapy (2% versus 5%, HR
0.42, 95% CI 0.18–0.99), whereas the incidence of all-cause death was similar between the rivaroxaban and
standard therapy groups (16% versus 18%, HR 0.93, 95% CI 0.64–1.35). Overall, rivaroxaban showed a
significant advantage compared with enoxaparin/VKA in patients with active cancer with regards to
incidence of major bleeding and net clinical benefit, consistent with the overall result of the pooled
analysis of the EINSTEIN DVT and EINSTEIN PE studies [57, 58].
Consideration has been given in recent guidelines to the question of whether to test patients for inherited
or acquired thrombophilia, which may be a risk factor for VTE recurrence. Broadly speaking, the presence
of an inherited thrombophilia is a more powerful risk factor for a first VTE than for recurrence [48]. The
UK National Institute for Health and Care Excellence (NICE) guidance suggests considering testing for
thrombophilia if cessation of anticoagulant treatment is planned and the patient’s initial thrombosis was
unprovoked, and if there is a first-degree relative who has previously sustained a DVT or PE [9].
Additionally, the ESC and European Respiratory Society recommend thrombophilia screening, including
antiphospholipid (lupus anticoagulant and anticardiolipin) antibodies, in patients with CTEPH [54].
Thrombophilia testing is not recommended in patients with an initial PE with known risk factors or in
those continuing anticoagulation [9].
The well-documented high incidence of major bleeding with long-term VKA therapy (∼5–9% per annum
in observational studies [59–61]) may deter long-term anticoagulation. The bleeding profile of long-term
direct OAC therapy is, therefore, of great interest. Rivaroxaban, dabigatran and apixaban have all been
studied in long-term secondary-prevention studies and shown favourable outcomes with treatment
durations between 12 months and 3 years.
In the EINSTEIN EXT trial, rivaroxaban (20 mg once daily) was compared with placebo for 6 or
12 months in patients who had already received 6–12 months of VKA or rivaroxaban for treatment of an
initial symptomatic VTE [30]. Rivaroxaban provided an 82% RRR for recurrent VTE versus placebo
(incidences of 1.3% and 7.1%; p<0.001), and the incidence of major bleeding was minimal (0.7% of
patients receiving rivaroxaban and none of those given placebo) [30].
The RE-SONATE (Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term
Prevention of Recurrent Symptomatic VTE) study found that extended dabigatran (150 mg twice daily) for
patients who had received anticoagulant treatment for an initial VTE led to a 93% RRR in the incidence of
recurrent symptomatic VTE compared with placebo (incidences of 0.4% and 5.6%, respectively; p<0.001).
Major bleeding occurred in 0.3% of those given dabigatran and in none of those given placebo [62]. In the
RE-MEDY (Secondary Prevention of Venous Thrombo Embolism) study, dabigatran (150 mg twice daily) was
also noninferior to warfarin as extended therapy after successful initial VTE treatment (incidence of recurrent
VTE 1.8% versus 1.3%; p=0.01 for noninferiority), with a similar incidence of major bleeding (HR 0.52, 95%
CI 0.27–1.01) but a higher frequency of acute coronary syndrome events (0.9% versus 0.2%; p=0.02) [62].
In the AMPLIFY-EXT trial, apixaban (2.5 or 5 mg twice daily) provided an 81% RRR in recurrent VTE or
VTE-related death compared with placebo (1.7% for both apixaban doses versus 8.8%; p<0.001) with
major bleeding in ⩽0.5% of patients in all treatment arms [63]. In this study, patients who had been
treated for 6–12 months with standard anticoagulant therapy or had completed treatment with apixaban
in the AMPLIFY trial (i.e. at a dose of 10 mg twice daily initially for acute treatment, then 5 mg twice
daily from 7 days to 6 months) received extended anticoagulation at this dose or 2.5 mg twice daily for a
further 12 months. This type of step-down dosing for the long-term secondary prevention of VTE, which
takes into account the decreasing risk of VTE recurrence over time and the need to minimise the risk of
bleeding, is an attractive idea in principle.
One way of stepping down therapy is for patients to receive acetylsalicylic acid (ASA) for the long-term
prevention of recurrent VTE, and this has been investigated in two randomised, double-blind studies. In
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WARFASA (the Warfarin and Aspirin Study), patients had completed 6–18 months of OAC therapy for
an initial event and were then randomised to ASA 100 mg once daily or placebo for at least another
2 years [64]. VTE recurred at a significantly lower rate in patients who received ASA (6.6% versus 11.2%
per year, HR 0.58, 95% CI 0.36–0.93) and only one patient in each treatment arm experienced major
bleeding [64]. By contrast, in the similarly designed ASPIRE (Aspirin to Prevent Recurrent Venous
Thromboembolism) study, ASA was not significantly more protective than placebo for secondary
prevention of VTE in patients who had received anticoagulant treatment for an initial VTE (p=0.09).
Despite this, ASA did lead to a reduction in the composite rate of VTE, myocardial infarction, stroke and
cardiovascular death compared with placebo (p=0.01), without a significant increase in major bleeding
(p=0.22) [65].
Reduced-dose anticoagulation and the use of ASA for long-term secondary VTE prevention will be further
investigated in the EINSTEIN CHOICE study, in which patients who have completed 6 or 12 months of
anticoagulation treatment for initial VTE will be randomised to 12 months of further treatment with either
rivaroxaban 20 mg once daily (as in EINSTEIN EXT), rivaroxaban 10 mg once daily or ASA 100 mg once
daily (https://clinicaltrials.gov/ct2/show/NCT02064439). The next question will be how to determine which
patients receive which treatment at which dose, most likely guided by assessment of risk factors for
recurrent thrombosis and bleeding.
Based on the results of the AMPLIFY [32], EINSTEIN [58] and RE-COVER [44] studies, and subsequent
approvals in Europe, the ESC now recommends apixaban (10 mg twice daily for 7 days followed by 5 mg
twice daily), rivaroxaban (15 mg twice daily for 21 days followed by 20 mg once daily) and dabigatran
(150 mg twice daily after standard parenteral anticoagulation in the acute phase, or 110 mg twice daily for
patients >80 years of age or those under concomitant verapamil treatment) for the treatment and
secondary prevention of VTE. Administration of edoxaban is also recommended by the ESC, based on the
results of the Hokusai-VTE study [34], as an alternative to VKA treatment following acute-phase
parenteral anticoagulation, despite not currently being approved in the European Union or the USA for
VTE treatment. All four direct OACs have received the Class 1B level of recommendation, suggesting that
they are equivalent to the established standard of care [10].
Inpatient versus outpatient management of PE
Haemodynamically unstable, high-risk PE patients will most likely present to the emergency department.
However, low- and intermediate-risk patients may present to and begin anticoagulant treatment within a
variety of hospital departments. This variable patient pathway has led to the emergence in several hospitals
of a dedicated PE service, which may coordinate the different specialties required to confirm the diagnosis
and manage ongoing treatment.
Dedicated PE services are also well placed to identify those low-risk patients who may be appropriate for
outpatient care overseen by their general practitioner or an acute medical unit, and to facilitate the
transition from hospital treatment to community care. The Hestia (Efficacy and safety of home treatment
versus in hospital treatment with LMWH in patients with non-massive pulmonary embolism) study, which
included a group of patients with asymptomatic right ventricular dysfunction on CTPA, concluded that
outpatient treatment of acute PE may be effective and safe in patients selected using predefined and
easy-to-use criteria, on the basis of observed low recurrence, mortality and bleeding rates [66]. With
continual improvements in scanning technology, an increasing number of small pulmonary emboli are
being detected, many of which are located in segmental and subsegmental vessels [67]. Clinical data have
suggested that treating patients with these presentations with anticoagulants may not be necessary in the
absence of cardiopulmonary compromise, concurrent DVT or persistent risk factors for recurrent VTE
[68, 69]. However, a recent analysis of 3728 patients with clinically suspected PE found a similar
prevalence of VTE risk factors and 3-month risk of recurrent VTE and mortality in patients with
subsegmental PE as in those with more proximal PE [70], suggesting that these presentations should be
taken seriously, at least when symptoms or other factors are present. These patients could be candidates
for outpatient treatment, particularly now that direct OAC treatment is an option.
Studies investigating the treatment of low-risk PE in the community have generally provided positive
results; however, none has included direct OACs. An open-label, multicentre, randomised trial compared
outpatient and in-hospital treatment of 344 patients with low-risk PE as judged by the PESI score [71].
Only one outpatient had recurrent VTE within 90 days (versus no inpatients; p=0.011 for noninferiority)
and three had major bleeding (compared with no inpatients; p=0.086); one patient in each group died.
Retrospective analyses conducted in Ireland [72] and Canada [73, 74] also support the concept of
outpatient treatment of low-risk PE. The largest dataset comes from a meta-analysis of published studies,
in which ZONDAG et al. [75] compared outcomes in 1657 patients with low-risk PE treated either entirely
in hospital, discharged within 72 h or treated solely as outpatients. There was no statistical difference in
492 DOI: 10.1183/16000617.00006614
PULMONARY EMBOLISM | R. LIMBREY AND L. HOWARD
the incidence of recurrent VTE (1.1–1.7%), major bleeding (0.8–1.0%) or mortality (0.7–2.3%) among the
three patient groups [75]. The incidence of mortality among outpatients was 1.9%, but this decreased to
0.6% when studies with an over-representation of patients with cancer were excluded. However, a Spanish
study that randomised patients with PE to early discharge or inpatient care was stopped early because of
an unexpectedly high short-term mortality rate in the early-discharge group, despite the patients included
being deemed low risk [76].
A number of centres have now established outpatient PE services, often working with acute medical units
and haematology departments to aid the streamlining of patients undergoing investigation for possible PE
and to manage ongoing outpatient care. The organisation and functioning of such a multidisciplinary
system is challenging, and the relevant specialist departments must be actively involved in drawing up
patient pathways and following standard procedures. Collaboration between specialties is vital.
Dedicated PE follow-up clinics can review the severity of PE sustained, and any ongoing right heart injury
and subsequent pulmonary hypertension. Up to 50% of patients with PE will have signs of right heart strain
at presentation [2, 77]. PENGO et al. [4] suggested that up to 4% of such patients go on to develop pulmonary
hypertension at 2 years. They did not see any significant additional increase in cases after this time.
In PE clinics, provoking factors can be assessed, ongoing risk determined and advice on length of
anticoagulation provided. The clinical utility of thrombophilia testing can be discussed and offered if
deemed helpful. For patients with coexistent DVT, legs can be assessed for post-thrombotic syndrome and
the use of compression stockings discussed. Current evidence does not show any benefit for above-knee
stockings compared with those that extend to below the knee [78]. Compression stockings are
recommended to be worn for 2 years after a DVT and for longer if signs of venous insufficiency persist
[8]. However, the recently reported 2-year SOX trial (Compression Stockings to Prevent the Post-
Thrombotic Syndrome After Symptomatic Proximal Deep Venous Thrombosis) did not find a benefit for
stockings over placebo for prevention of post-thrombotic syndrome after a first proximal DVT [79].
Finally, when anticoagulant therapy has been completed, advice can be given regarding lessening an
individual’s risk of recurrent thrombosis during future high-risk scenarios, e.g. long-haul flights (4 h or
longer). In this case, those who have sustained a minor provoked PE might be advised, in addition to
standard advice on the use of compression stockings and the maintenance of hydration and mobility, to
consider a prophylactic dose of LMWH prior to each leg of a flight [80]. This mode of management is in
line with the current model of personalised medicine.
Developments in the management and treatment of PE: implications for
clinical practice
The development of direct OACs for ongoing anticoagulant treatment provides an opportunity to simplify
anticoagulation management and facilitate the transition from inpatient to outpatient care. Fixed doses for
treatment, coupled with predictable pharmacokinetics and pharmacodynamics regardless of demographic
factors, obviate the requirement for routine coagulation monitoring and dose adjustment [29]. Of the
direct OACs currently licensed for VTE treatment, rivaroxaban provides the option of using a single oral
drug from treatment initiation for the total duration of anticoagulation, whereas dabigatran is licensed for
use after standard heparin induction. Both approaches have been shown to be effective for the treatment
of initial VTE and for long-term secondary prevention [30, 31, 33, 62]. Rivaroxaban has also been tested
successfully for the specific treatment of PE [31].
Against this, limitations such as the lack of specific reversal agents for bleeding emergencies must be
considered [40]. However, it is important to note that acute treatment trials showed that direct OACs did not
increase the incidence of major bleeding compared with enoxaparin/VKA (and in the case of rivaroxaban
and apixaban, the risk of major bleeding was decreased) [30–34], and that there was no substantial increase
in major bleeding with direct OACs versus placebo in long-term extension studies [30, 62, 63]. Nevertheless,
concern remains regarding those rare incidences in which immediate reversal may be required. In bleeding
emergencies in patients taking direct OACs, standard strategies should be implemented with consideration of
pro-haemostatic agents such as prothrombin complex concentrate. Newly developed specific reversal agents
for direct factor Xa and thrombin inhibitors are under investigation [40, 81, 82]. For non-life-threatening
bleeding, temporary or permanent treatment discontinuation may be sufficient, particularly given the short
half-life of the direct OACs (5–17 h) [83] compared with, for example, warfarin (20–60 h) [39].
The initial upfront costs of direct OACs are higher than those of enoxaparin/VKA therapy, but in the UK,
NICE concluded that rivaroxaban was cost-effective for VTE treatment on the basis of the decreased use
of healthcare resources for coagulation monitoring [84]. Although the use of direct OACs should ease the
burden on community services, it may also provide fewer opportunities for physicians to monitor patient
compliance and wellbeing. Specialist PE clinics, engaging with primary-care physicians, will assess
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response to treatment and requirement for longer-term anticoagulation. A potential protocol for the
stratified treatment of patients with PE is presented in figure 2. Outpatient treatment with direct OACs
will be possible for many patients, and it may be particularly appropriate for those who cannot tolerate
warfarin or those for whom dose adjustments with VKAs may be particularly burdensome (e.g. the
elderly). Additionally, the increasing sensitivity of imaging techniques may lead to identification of a larger
number of cases of low-risk PE, and these patients may be suitable for early discharge; direct OACs may
facilitate the transition from hospital to home in this scenario.
Haemodynamically unstable patients and those with CrCl <15 mL·min−1 (<30 mL·min−1 for dabigatran)
are not appropriate for treatment with direct OACs. There are also limited data in patients with CrCl 15–
29 mL·min−1 (not included in phase III trials) and those with cancer (of whom there were few in these
studies) [30–34]. Patients with complications such as CTEPH may be candidates for direct OAC treatment,
but should be referred to a specialist centre [54]. If a patient is not considered appropriate for, or does not
wish to continue, long-term anticoagulant treatment, ASA could be considered for extended secondary
prevention of VTE. However, data on its efficacy are equivocal and the magnitude of the protective effect
appears more modest (∼40% RRR in recurrent VTE versus placebo) [64, 65] than that with the direct
OACs (∼80–90% RRR) [30, 62, 63]. Further studies in this area are ongoing.
In addition to providing an important further option for the management of PE, direct OACs are already
in use in other settings, including VTE prophylaxis after major orthopaedic surgery, stroke prevention in
patients with nonvalvular atrial fibrillation and, in the case of rivaroxaban, prevention of cardiovascular
events in patients with acute coronary syndrome. Increasing use will provide us with information on the
currently unknown pitfalls as well as the advantages of these new, direct OACs.
Consider outpatient
treatment with direct OAC
Low-risk PE
Intermediate-low-
risk PE
In-hospital anticoagulant
treatment: LMWH/VKA or 
direct OAC
Intermediate-high-
risk PE
High-risk PE Thrombolysis§ Supportive hospital care
Outpatient treatment
If clinically stable
Consider if haemodynamic
decompensation occurs
Circumstances requiring 
in-hospital observation
No special clinical
circumstances#
Test for thrombophilia if
  required¶
Investigate for malignancy 
  if indicated
Determine length of
  anticoagulation considering
  risk of bleeding and
  recurrent VTE+
Diagnosis
and risk
stratification
PE clinic Primary care
FIGURE 2 Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants
(OACs). Risk groups correspond to the European Society of Cardiology guidelines for stratification by 30-day mortality
risk, i.e. high-risk PE: patient is haemodynamically unstable (high risk of death; calculation of clinical risk score not
necessary); intermediate-high-risk PE: patient is without shock or hypotension but has a clinical risk score suggestive of
PE and indicative of high 30-day mortality risk (Pulmonary Embolism Severity Index (PESI) class III–V/simplified (s)
PESI ⩾1 point), and is positive for both signs of right ventricular (RV) dysfunction on an imaging test and by means of
cardiac laboratory biomarkers indicative of myocardial injury or heart failure as a result of RV dysfunction;
intermediate-low-risk PE: patient is without shock or hypotension but has a clinical risk score suggestive of PE (PESI
I–II or III–IV/sPESI ⩾0) and may have either one or none of the indicators for RV dysfunction; low-risk PE: patient is
without shock or hypotension, has PESI I–II/sPESI=0, and no signs of RV dysfunction [10]. LMWH: low molecular
weight heparin; VKA: vitamin K antagonist. #: may include patients with subsegmental PE; ¶: patient has initial
unprovoked thrombosis, has a first-degree relative with a history of venous thromboembolism (VTE) or has chronic
thromboembolic pulmonary hypertension; +: consider use of clinical risk scores to guide decision; §: high-risk patients
receiving thrombolysis are not recommended to receive direct OACs, and these patients were excluded from clinical
trials of direct OACs for VTE treatment.
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